Compare Cassava Sciences Inc (FLNA) vs Liquidia Corporation Common Stock (LQDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Liquidia Corporation Common Stock — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.34M), while Liquidia Corporation Common Stock trades at $34.27 (market cap $3.04B). The key difference: Liquidia Corporation Common Stock is far larger — about 86× Cassava Sciences Inc's market cap, and Liquidia Corporation Common Stock is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and Liquidia Corporation Common Stock for 0 Days on average.
| FLNA | LQDA | |
|---|---|---|
Market Cap | $35.34M | $3.04B |
Volume | 251,946 | 21,111,778 |
Sector | Health | Health |
52-Week High | $4.64 | $91.03 |
52-Week Low | $0.68 | $22.02 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | -$47.34M | $2.94B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.7434, down 3.39% today, with a bearish technical signal despite oscillator bullishness. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent FDA approval to lift the clinical hold on simufilam for TSC-related epilepsy is a positive development, with Phase 2a trials expected in early 2027.
Outlook remains speculative given negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include ongoing operational losses and dependence on clinical trial success. The stock presents high-risk biotech opportunity with potential upside from successful drug development.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Liquidia Corporation Common Stock
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →
